Enliven Therapeutics, Inc. $ELVN Stock: Profund Advisors LLC Increases Holdings

Profund Advisors LLC increased its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 260.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,874 shares of the company’s stock after buying an additional 20,148 shares during the quarter. Profund Advisors LLC’s holdings in Enliven Therapeutics were worth $1,278,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ELVN. KBC Group NV purchased a new stake in shares of Enliven Therapeutics during the first quarter worth about $38,000. Sterling Capital Management LLC increased its holdings in shares of Enliven Therapeutics by 1,180.7% during the third quarter. Sterling Capital Management LLC now owns 1,921 shares of the company’s stock valued at $88,000 after acquiring an additional 1,771 shares in the last quarter. State of Wyoming purchased a new position in shares of Enliven Therapeutics in the 2nd quarter valued at approximately $96,000. ProShare Advisors LLC raised its position in shares of Enliven Therapeutics by 29.5% in the 3rd quarter. ProShare Advisors LLC now owns 9,852 shares of the company’s stock valued at $452,000 after purchasing an additional 2,246 shares during the last quarter. Finally, FNY Investment Advisers LLC purchased a new position in shares of Enliven Therapeutics in the 2nd quarter valued at approximately $126,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $38.48, for a total value of $231,572.64. Following the completion of the sale, the chief financial officer owned 38,000 shares of the company’s stock, valued at approximately $1,462,240. This trade represents a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total value of $606,710.00. Following the transaction, the director owned 13,000 shares in the company, valued at approximately $606,710. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 31,054 shares of company stock valued at $1,493,823. 3.00% of the stock is owned by corporate insiders.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN opened at $44.63 on Tuesday. The company’s fifty day moving average price is $48.40 and its 200 day moving average price is $42.67. Enliven Therapeutics, Inc. has a 1 year low of $14.78 and a 1 year high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, analysts anticipate that Enliven Therapeutics, Inc. will post -1.79 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Stifel Nicolaus upped their price target on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wall Street Zen downgraded shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. William Blair began coverage on shares of Enliven Therapeutics in a research note on Tuesday, August 18th. They set an “outperform” rating for the company. Zacks Research lowered shares of Enliven Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 13th. Finally, Guggenheim reissued a “buy” rating on shares of Enliven Therapeutics in a research report on Thursday, October 8th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $75.44.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.